pTRIPZ shTREX1
(Plasmid
#127700)
-
PurposeDoxycyclin inducible shRNA knockdown of both human and mouse TREX1 gene
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 127700 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepTRIPZ RFP+
- Backbone size w/o insert (bp) 13320
- Total vector size (bp) 13412
-
Modifications to backboneinsertion of mouse TREX1 specific shRNA hairpin sequence between XhoI and Eco RI restriction sites
-
Vector typeMammalian Expression, Lentiviral
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameshTREX1
-
gRNA/shRNA sequenceTGCTCAGCATCTGTCAGTGGAG
-
SpeciesH. sapiens (human), M. musculus (mouse)
-
GenBank ID22040
-
Entrez GeneTrex1 (a.k.a. AU041952)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site XhoI (not destroyed)
- 3′ cloning site EcoRI (not destroyed)
- 5′ sequencing primer cagaaggctcgagaaggtatattgctgttgctgttgacagtgagcg
- 3′ sequencing primer ctaaagtagccccttgaattccgaggcagtaggca (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pTRIPZ shTREX1 was a gift from Sandra Demaria (Addgene plasmid # 127700 ; http://n2t.net/addgene:127700 ; RRID:Addgene_127700) -
For your References section:
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. Nat Commun. 2017 Jun 9;8:15618. doi: 10.1038/ncomms15618. 10.1038/ncomms15618 PubMed 28598415